Advanced search
Publication Cover
Therapeutic Delivery Volume 3, 2012 - Issue 11
Submit an article Journal homepage
210
Views
0
CrossRef citations to date
0
Altmetric
Review

Tight Junctions in Skin: New Perspectives

Bharti Sapraa Pharmaceutics Division Department of Pharmaceutical Sciences Punjabi UniversityPatialaIndia
,
Manish Jindala Pharmaceutics Division Department of Pharmaceutical Sciences Punjabi UniversityPatialaIndia
&
Ashok K Tiwaryb Pharmaceutics Division Department of Pharmaceutical Sciences Punjabi [email protected]
Pages 1297-1327 | Published online: 23 Nov 2012

References

  • Briggman JV , BankHL, BigelowJB, GravesJS, SpicerSS. Structure of the tight junctions of the human eccrine sweat gland. Am. J. Anat.162, 357–368 (1981).
  • Schneeberger EE , LynchRD. The tight junction: a multifunctional complex. Am. J. Physiol. Cell Physiol.286, C1213–C1228 (2004).
  • Matter K , AijazS, TsaparaA, BaldaMS. Mammalian tight junctions in the regulation of epithelial differentiation and proliferation. Curr. Opin. Cell. Biol.17, 453–458 (2005).
  • Brandner JM . Tight junctions and tight junction proteins in mammalian epidermis. Eur. J. Pharm. Biopharm.72, 289–294 (2009).
  • Furuse M , HataM, FuruseKet al. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J. Cell. Biol. 156, 1099–1111 (2002).
  • Furuse M , TsukitaS. Claudins in occluding junctions of humans and flies. Trends Cell Biol.16, 181–188 (2006).
  • Ebnet K , SuzukiA, OhnoS, VestweberD. Junctional adhesion molecules (JAMs): more molecules with dual functions? J. Cell Sci.117, 19–29 (2004).
  • Ludwig RJ , ThomasM, ZollnerWet al. Junctional adhesion molecules (JAM)-B and -C contribute to leukocyte extravasation to the skin and mediate cutaneous inflammation. J. Invest. Dermatol. 125, 969–976 (2005).
  • Furuse M , HiraseT, ItohMet al. Occludin: a novel integral membrane protein localizing at tight junctions. J. Cell. Biol. 123, 1777–1788 (1993).
  • Pummi K , MalminenM, AhoH, Karvonen S-L, Peltonen J, Peltonen S. Epidermal tight junctions: ZO-1 and occludin are expressed in mature, developing, and affected skin and in vitro differentiating keratinocytes. J. Invest. Dermatol.117, 1050–1058 (2001).
  • Morita K , ItohM, SaitouMet al. Subcellular distribution of tight junction-associated proteins (occludin, ZO-1, ZO-2) in rodent skin. J. Invest. Dermatol. 110, 826–862 (1998).
  • Aijaz S , BaldaMS, MatterK. Tight junctions: molecular architecture and function. Int. Rev. Cytol.248, 261–298 (2006).
  • Yu AL , McCarthyKM, FrancisSAet al. Knock down of occluding expression leads to diverse phenotypic alterations in epithelial cells. Am. J. Physiol. Cell Physiol. 288, C1231–C1241 (2005).
  • Wang Z , MandellKJ, ParkosCA, MrsnyRJ, NusratA. The second loop of occludin is required for suppression of Raf1-induced tumor growth. Oncogene24, 4412–4420 (2005).
  • Saitou M , FuruseM, SasakiHet al. Complex phenotype of mice lacking occludin, a component of tight junction strands. Mol. Biol. Cell 11, 4131–4142 (2000).
  • Furuse M , FujitaK, HiiragiT, FujimotoK, TsukitaS. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J. Cell. Biol.29, 1539–1550 (1998).
  • Shin K , FoggVC, MargolisB. Tight junctions and cell polarity. Annu. Rev. Cell Dev. Biol.22, 207–235 (2006).
  • Anderson JM , Van Itallie CM, Fanning AS. Setting up a selective barrier at the apical junction complex. Curr. Opin. Cell Biol.16, 140–145 (2004).
  • Furuse M , TsukitaS. Claudins in occluding junctions of humans and flies. Trends Cell Biol.16, 181–188 (2006).
  • Ikenouchi J , FuruseM, FuruseK, SasakiH, TsukitaS. Tricellulin constitutes a novel barrier at tricellular contacts of epithelial cells. J. Cell. Biol.171, 939–945 (2005).
  • Riazuddin S , AhmedZM, FanningASet al. Tricellulin is a tight-junction protein necessary for hearing. Am. J. Hum. Genet. 79, 1040–1051 (2006).
  • Fanning AS , MaTY, AndersonJM. Isolation and functional characterization of the actin binding region in the tight junction protein ZO-1. FASEB J.16, 1835–1837 (2002).
  • Umeda K , IkenouchiJ, Katahira-TayamaSet al. ZO-1 and ZO-2 independently determine where claudins are polymerized in tight-junction strand formation. Cell 126, 741–754 (2006).
  • Matter K , BaldaMS. Epithelial tight junctions, gene expression and nucleo-junctional interplay. J. Cell Sci.120, 1505–1511 (2007).
  • Makarova O , RohMH, LiuCJ, LaurinecS, MargolisB. Mammalian Crumbs3 is a small transmembrane protein linked to protein associated with Lin-7 (Pals1). Gene302, 21–29 (2003).
  • Bazzoni G . The JAM family of junctional adhesion molecules. Curr. Opin. Cell Biol.15, 525–530 (2003).
  • Lemmers C , MichelD, Lane-GuermonprezLet al. CRB3 binds directly to Par6 and regulates the morphogenesis of the tight junctions in mammalian epithelial cells. Mol. Biol. Cell 15, 1324–1333 (2004).
  • Osler ME , ChangMS, BaderDM. Bves modulates epithelial integrity through an interaction at the tight junction. J. Cell Sci.118, 4667–4678 (2005).
  • Meyer TN , SchwesingerC, DenkerBM. Zonula occludens-1 is a scaffolding protein for signaling molecules. Galpha(12) directly binds to the Src homology 3 domain and regulates paracellular permeability in epithelial cells. J. Biol. Chem.277, 24855–24858 (2002).
  • Guillemot L , HammarE, KaisterCet al. Disruption of the cingulin gene does not prevent tight junction formation but alters gene expression. J. Cell Sci. 117, 5245–5256 (2004).
  • Aijaz S , D‘AtriF, CitiS, BaldaMS, MatterK. Binding of GEF-H1 to the tight junction-associated adaptor cingulin results in inhibition of Rho signaling and G1/S phase transition. Dev. Cell8, 777–786 (2005).
  • Balda MS , WhitneyJA, FloresC, GonzálezS, CereijidoM, MatterK. Functional dissociation of paracellular permeability and transepithelial electrical resistance and disruption of the apical-basolateral intramembrane diffusion barrier by expression of a mutant tight junction membrane protein. J. Cell. Biol.134, 1031–1049 (1996).
  • Balda MS , MatterK. The tight junction protein ZO-1 and an associated Y-box transcription factor regulate ErbB-2 expression. EMBO J.19, 2024–2033 (2000).
  • Elkouby-Naor L , AbassiZ, LagzielA, GowA, Ben-YosefT. Double gene deletion reveals lack of cooperation between claudin 11 and claudin 14 tight junction proteins. Cell Tissue Res.333, 427–438 (2008).
  • Dejana E , Tournier-LasserveE, WeinsteinBM. The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. Dev. Cell16, 209–221 (2009).
  • Krause G , WinklerL, MuellerSL, HaseloffRF, PiontekJ, BlasigIE. Structure and function of claudins. Biochim. Biophys. Acta1778, 631–645 (2008).
  • Van ICM , AndersonJM. Claudins and epithelial paracellular transport. Annu. Rev. Physiol.68, 403–429 (2006).
  • Waheed F , SpeightP, KawaiG, DanQ, KapusA, SzásziK. Extracellular signal-regulated kinase and GEF-H1 mediate depolarization-induced Rho activation and paracellular permeability increase. Am. J. Physiol. Cell Physiol.298, C1376–C1387 (2010).
  • Yuki T , YoshidaH, AkazawaY, KomiyaA, SugiyamaY, InoueS. Activation of TLR2 enhances tight junction barrier in epidermal keratinocytes. J. Immunol.187, 3230–3237 (2011).
  • McLaughlin J , PadfieldPJ, BurtJPet al. Ochratoxin A increases permeability through tight junctions by removal of specific claudin isoforms. Am. J. Physiol. Cell Physiol. 287, C1412–C1417 (2004).
  • Lambert D , PadfieldPJ, McLaughlinJet al. Ochratoxin A displaces claudins from detergent resistant membrane microdomains. Biochem. Biophys. Res. Commun. 358, 632–636 (2007).
  • Yuki T , HachiyaA, KusakaAet al. Characterization of tight junctions and their disruption by UVB in human epidermis and cultured keratinocytes. J. Invest. Dermatol. 131, 744–752 (2011).
  • Furuse M , HataM, FuruseKet al. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J. Cell. Biol. 156, 1099–1111 (2002).
  • Troy TC , ArabzadehA, LariviereNMK, EnikanolaiyeA, TurksenK. Dermatitis and aging-related barrier dysfunction in transgenic mice overexpressing an epidermal-targeted claudin 6 tail deletion mutant. PLoS ONE4, e7814 (2009).
  • Lin JE , SnookAE, LiPet al. GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity. PLoS ONE 7, e31686 (2012).
  • Sourisseau T , GeorgiadisA, TsaparaAet al. Regulation of PCNA and cyclin D1 expression and epithelial morphogenesis by the ZO-1-regulated transcription factor ZONAB/DbpA. Mol. Cell. Biol. 26, 2387–2398 (2006).
  • Katsuno T , UmedaK, MatsuiTet al. Deficiency of ZO-1 causes embryonic lethal phenotype associated with defected yolk sac angiogenesis and apoptosis of embryonic cells. Mol. Biol. Cell 19, 2465–2475 (2008).
  • Kohler K , ZahraouiA. Tight junction: a co-ordinator of cell signaling and membrane trafficking. Biol. Cell97, 659–665 (2005).
  • Heasman SJ , RidleyAJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat. Rev. Mol. Cell Biol.9, 690–701 (2008).
  • Coggeshall RE . A fine structural analysis of the epidermis of the earthworm, Lumbricus terrestris. L. J. Cell. Biol.28, 95–108 (1966).
  • Horakl E , LelkesG, SugarJ. Intercellular junctions of methylcholanthrene-induced rat skin basocellular and squamous carcinomas. Br. J. Cancer49, 637–644 (1984).
  • Morita K , FuruseM, YoshidaYet al. Molecular architecture of tight junctions of periderm differs from that of the maculae occludentes of epidermis. J. Invest. Dermatol. 118, 1073–1079 (2002).
  • Elias PM , MatsuyoshiN, WuHet al. Desmoglein isoform distribution affects stratum corneum structure and function. J. Cell. Biol. 153, 243–249 (2001).
  • Sevilla LM , NachatR, GrootKRet al. Mice deficient in involucrin, envoplakin, and periplakin have a defective epidermal barrier. J. Cell. Biol. 179, 1599–1612 (2007).
  • Sandilands A , O‘ReganGM, LiaoHet al. Prevalent and rare mutations in the gene encoding filaggrin cause ichthyosis vulgaris and predispose individuals to atopic dermatitis. J. Invest. Dermatol. 126, 1770–1775 (2006).
  • Barker JN , PalmerCN, ZhaoYet al. Null mutations in the filaggrin gene (FLG) determine major susceptibility to early-onset atopic dermatitis that persists into adulthood. J. Invest. Dermatol. 127, 564–567 (2007).
  • Baurecht H , IrvineAD, NovakNet al. Toward a major risk factor for atopic eczema: meta-analysis of filaggrin polymorphism data. J. Allergy Clin. Immunol. 120, 1406–1412 (2007).
  • Nomura T , SandilandsA, AkiyamaMet al. Unique mutations in the filaggrin gene in Japanese patients with ichthyosis vulgaris and atopic dermatitis. J. Allergy Clin. Immunol. 119, 434–440 (2007).
  • Jungersted JM , ScheerH, MempeMet al. Stratum corneum lipids, skin barrier function and filaggrin mutations in patients with atopic eczema. Allergy65, 911–918 (2010).
  • O‘Regan M , IrvineAD. The role of filaggrin in the atopic diathesis. Clin. Expt. Allergy40, 965–972 (2010).
  • Benedetto AD , RafaelsNM, McGirtLYet al. Tight junction defects in patients with atopic dermatitis. J. Allergy Clin. Immunol. 127, 773–786 (2011).
  • Ishida-Yamamoto A , KishibeM, IizukaH. Epidermal structure and function. J. Invest. Dermatol.132, S51–S64 (2012).
  • Mitic LL , AndersonJM. Molecular architecture of tight junctions. Annu. Rev. Physiol.60, 121–142 (1998).
  • Matthew JH , SisiP, BanburyDN, ByrneC. Patterned acquisition of skin barrier function during development. Development125, 1541–1552 (1998).
  • Brandner JM , KiefS, WladykowskiE, HoudekP, MollI. Tight junction proteins in the skin. Skin Pharmacol. Physiol.19, 71–77 (2006).
  • Helfrich I , SchmitzA, ZigrinoPet al. Role of aPKC isoforms and their binding partners Par3 and Par6 in epidermal barrier formation. J. Invest. Dermatol. 127, 782–791 (2007).
  • Peltonen S , RiehokainenJ, PummiK, PeltonenJ. Tight junction components occludin, ZO-1, and claudin-1, -4 and -5 in active and healing psoriasis. Br. J. Dermatol.156, 466–472 (2007).
  • Jones SM , JonesJC, GoldmanRD. Fractionation of desmosomes and comparison of the polypeptide composition of desmosomes prepared from two bovine epithelial tissues. J. Cell. Biochem.36, 223–236 (1988).
  • Pillai S , BikleDD, Mancianti M-L, Cline P, Hincenbergs M. Calcium regulation of growth and differentiation of normal human keratinocytes: modulation of differentiation competence by stages of growth and extracellular calcium. J. Cell. Physiol.143, 294–302 (1990).
  • Kirschner N , PoetzlC, von den Driesch P et al. Alteration of tight junction proteins is an early event in psoriasis putative involvement of proinflammatory cytokines. Am. J. Pathol.175, 1095–1106 (2009).
  • Elias PM , GhadiallyR. The aged epidermal permeability barrier: basis for functional abnormalities. Clin. Geriatr. Med.18, 103–120 (2002).
  • Ward S . Eczema and dry skin in older people: identification and management. Br. J. Community Nurs.10, 453–456 (2005).
  • Makrantonaki E , ZouboulisCC. Molecular mechanisms of skin aging: state of the art. Ann. N. Y. Acad. Sci.1119, 40–50 (2007).
  • Davies A . Management of dry skin conditions in older people. Br. J. Community Nurs.13, 254–257 (2008).
  • Kirschnera N , HoudekaP, FrommbM, MollaI, JohannaMB. Tight junctions form a barrier in human epidermis. Eur. J. Cell. Biol.89, 839–842 (2010).
  • Watson REB , PoddarR, WalkerJMet al. Altered claudin expression is a feature of chronic plaque psoriasis. J. Pathol. 212, 450–458 (2007).
  • Butcher EC , PickerLJ. Lymphocyte homing and homeostasis. Science272, 60–66 (1996).
  • Von Andrian UH , MackayCR. T-cell function and migration. Two sides of the same coin. N. Engl. J. Med.343, 1020–1034 (2000).
  • Muller WA . Leukocyte–endothelial–cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol.24, 327–334 (2003).
  • Schon MP , ZollnerTM, BoehnckeWH. The molecular basis of lymphocyte recruitment to the skin: clues for pathogenesis and selective therapies of inflammatory disorders. J. Invest. Dermatol.121, 951–962 (2003).
  • Weber C . Novel mechanistic concepts for the control of leukocyte transmigration: specialization of integrins, chemokines, and junctional molecules. J. Mol. Med.81, 4–19 (2003).
  • Tunggal JA , HelfrichI, SchmitzAet al. E-cadherin is essential for in vivo epidermal barrier function by regulating tight junctions. EMBO J. 24, 1146–1156 (2005).
  • Brabletz T , HlubekF, SpadernaSet al. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs 179, 56–65 (2005).
  • Margaryan NV , StrizziL, AbbottDEet al. EphA2 as a promoter of melanoma tumorigenicity. Cancer Biol. Ther. 8, 279–288 (2009).
  • Udayakumar D , ZhangG, JiZ, NjauwCN, MrozP, TsaoH. Epha2 is a critical oncogene in melanoma. Oncogene30, 4921–4929 (2011).
  • Guo H , MiaoH, GerberLet al. Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin. Cancer Res. 66, 7050–7058 (2006).
  • Dalgarno DC , BotfieldMC, RicklesRJ. SH3 domains and drug design: ligands, structure, and biological function. Biopolymers43, 383–400 (1997).
  • Missiaglia E , BlaveriE, TerrisBet al. Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis. Int. J. Cancer 112, 100–112 (2004).
  • Resnick MB , GavilanezM, NewtonEet al. Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation. Hum. Pathol. 36, 886–892 (2005).
  • Tokes AM , KulkaJ, PakuSet al. The expression of five different claudins in invasive breast carcinomas: comparison of pT1pN1 and pT1pN0 tumors. Pathol. Res. Pract. 201, 537–544 (2005).
  • Russell LJ , DiGiovannaJJ, RogersGRet al. Mutations in the gene for transglutaminase 1 in autosomal recessive lamellar ichthyosis. Nat. Genet. 9, 279–284 (1995).
  • Huber M , RettlerI, BernasconiKet al. Mutations of keratinocyte transglutaminase in lamellar ichthyosis. Science 267, 525–528 (1995).
  • Arabzadeh A , TroyTC, TurksenK. Changes in the distribution pattern of claudin tight junction proteins during the progression of mouse skin tumorigenesis. BMC Cancer7, 196 (2007).
  • Langbein L , Pape U-F, Grund C et al. Tight junction-related structures in the absence of a lumen: occluding claudins and tight junction plaque proteins in densely packed cell formations of stratified epithelia and squamous cell carcinomas. Eur. J. Cell. Biol.82, 385–400 (2003).
  • Morita K , TsukitaS, MiyachiY. Tight junction-associated proteins (occludin, ZO-1, claudin-1, claudin-4) in squamous cell carcinoma and Bowen‘s disease. Br. J. Dermatol.151, 328–334 (2004).
  • Yoshida Y , MoritaK, MizoguchiA, IdeC, MiyachiY. Altered expression of occludin and tight junction formation in psoriasis. Arch. Dermatol. Res.293, 239–244 (2001).
  • Ohnemus U , KohrmeyerK, HoudekPet al. Regulation of epidermal tight-junctions (TJ) during infection with exfoliative toxin-negative Staphylococcus strains. J. Invest. Dermatol. 128, 906–916 (2008).
  • Lemini-Lopez A , Flores-RomoL, Arevalo-LopezA, MezaI. Altered morphology and distribution of cellular junction proteins in non-lesional psoriatic epidermis: an insight into disease severity. Arch. Med. Res.37, 36–44 (2006).
  • Boehnke K , MiranceaN, PavesioA, FusenigaNE, BoukampP, Stark H-J. Effects of fibroblasts and microenvironment on epidermal regeneration and tissue function in long-term skin equivalents. Eur. J. Cell. Biol.86, 731–746 (2007).
  • Sonoda N , FuruseM, SasakiHet al. Clostridium perfringens enterotoxin fragment removes specific claudins from tight junctionstrands: evidence for direct involvement of claudins in tight junction barrier. J. Cell. Biol.147, 195–204 (1999).
  • Langbein L , GrundC, KuhnCet al. Tight junctions and compositionally related junctional structures in mammalian stratified epithelia and cell cultures derived therefrom. Eur. J. Cell. Biol. 81, 419–435 (2002).
  • Yamamoto T , KurasawaM, HattoriTet al. Relationship between expression of tight junction-related molecules and perturbed epidermal barrier function in UVB-irradiated hairless mice. Arch. Dermatol. Res. 300, 61–68 (2008).
  • Amasheh S , SchmidtT, MahnMet al. Contribution of claudin-5 to barrier properties in tight junctions of epithelial cells. Cell Tissue Res. 321, 89–96 (2005).
  • Tanaka M , KamataR, SakaiR. EphA2 phosphorylates the cytoplasmic tail of claudin-4 and mediates paracellular permeability. J. Biol. Chem.280, 42375–42382 (2005).
  • Liu Y , NusratA, SchnellFJet al. Human junction adhesion molecule regulates tight junction resealing in epithelia. J. Cell Sci. 113, 2363–2374 (2000).
  • Aurrand-Lions M , Johnson-LegerC, WongC, Du Pasquier L, Imhof BA. Heterogeneity of endothelial junctions is reflected by differential expression and specific subcellular localization of the three JAM family members. Blood98, 3699–3707 (2001).
  • Donovan MD , FlynnGL, AmidonGL. The molecular weight dependence of nasal absorption: the effect of absorption enhancers. Pharm. Res.7, 808–815 (1990).
  • Liu DZ , LeCluyseEL, ThakkerDR. Dodecylphosphocholine-mediated enhancement of paracellular permeability and cytotoxicity in Caco-2 cell monolayers. J. Pharm. Sci.88, 1161–1168 (1999).
  • Tomita M , HayashiM, AwazuS. Absorption-enhancing mechanism of sodium caprate and decanoyl carnitine in Caco-2 cells. J. Pharmacol. Exp. Ther.272, 739–743 (1995).
  • Lindmark T , KimuraY, ArturssonP. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. J. Pharmacol. Exp. Ther.284, 362–369 (1998).
  • Cho SY , KimJS, LiH, ShimC, LinhardtRJ, KimYS. Enhancement of paracellular transport of heparin disaccharide across Caco-2 cell monolayers. Arch. Pharm. Res.25, 86–92 (2002).
  • De Benedetto A , KuboA, BeckLA. Skin barrier disruption: a requirement for allergen sensitization? J. Invest. Dermatol.132, 949–963 (2012).
  • Obata Y , SesumiT, TakayamaKet al. Evaluation of skin damage caused by percutaneous absorption enhancers using fractal analysis. J. Pharm. Sci. 89, 556–561 (2000).
  • Kaushal N , NazS, TiwaryAK. Angelica archengelica extract induced perturbation of rat skin and tight junctional protein (ZO-1) of HaCaT cells. Daru19(1), 1–11 (2011).
  • Kaushal N , JainS, PaturuK, TiwaryAK. Influence of piperine on transcutaneous permeation of repaglinide in rats and on tight junction proteins in HaCaT cells: unveiling the mechanisms for enhanced permeation. Sci. Pharm.77, 877–897 (2009).
  • Uchida T , KanazawaT, TakashimaY, OkadaH. Development of an efficient transdermal delivery system of small interfering RNA using functional peptides, Tat and AT-1002. Chem. Pharm. Bull.59, 196–201 (2011).
  • Vllasaliu D , Exposito-HarrisR, HerasAet al. Tight junction modulation by chitosan nanoparticles: comparison with chitosan solution. Int. J. Pharm. 15, 183–193 (2010).
  • Ranaldi G , MariglianoI, VespignaniI, PerozziG, SambuyY. The effect of chitosan and other polycations on tight junction permeability in the human intestinal Caco-2 cell line. J. Nutr. Biochem.13, 157–167 (2002).
  • Smith JM , DornishM, WoodEJ. Involvement of protein kinase C in chitosan glutamate-mediated tight junction disruption, Biomaterials26, 3269–3276 (2005).
  • Peixoto EB , Collares-BuzatoCB. Protamine-induced epithelial barrier disruption involves rearrangement of cytoskeleton and decreased tight junction-associated protein expression in cultured MDCK strains. Cell Struct. Funct.29, 165–178 (2005).
  • Salama NN , EddingtonND, FasanoA. Tight junction modulation and its relationship to drug delivery. Adv. Drug Deliv. Rev.58, 15–28 (2006).
  • Cox D , GaoH, RajeS, ScottK, EddingtonND. Enhancing the permeation of marker compounds and emaninone anticonvulsants across Caco-2 monolayers by modulating tight junctions using zonula occludens toxin. Eur. J. Pharm. Biopharm.52, 145–150 (2001).
  • Cox D , RajeS, GaoH, SalamaNN, EddingtonND. Enhanced permeability of molecular weight markers and poorly bioavailable compounds across Caco-2 monolayers using the absorption enhancer, zonula occludens toxin. Pharm. Res.19, 1680–1688 (2002).
  • Fasano A , UzzauS. Modulation of intestinal tight junctions by Zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. J. Clin. Invest.99, 1158–1164 (1997).
  • Tavelin S , HashimotoK, MalkinsonJ, LazorovaL, TothI, ArturssonP. A new principle for tight junction modulation based on occludin peptides. Mol. Pharmacol.64, 1530–1540 (2003).
  • Deli MA . Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim. Biophys. Acta.1788, 892–910 (2009).
  • Wong CH , MrukDD, LeeWM, ChengCY. Targeted and reversible disruption of the blood–testis barrier by an FSH mutant-occludin peptide conjugate. FASEB J.21, 438–448 (2007).
  • Gopalakrishnan SS , TripathiAA, AmirPet al. Larazotide acetate promotes tight junction assembly in epithelial cells. Peptides 35, 95–101 (2012).
  • Salama NN , FasanoA, ThakarM, EddingtonND. The impact of deltaG on the oral bioavailability of low bioavailable therapeutic agents. J. Pharmacol. Exp. Ther.312, 199–205 (2005).
  • Rojas R , RuizWG, Leung S-M, Jou T-S, Apodaca G. Cdc42-dependent modulation of tight junctions and membrane protein traffic in polarized Madin-Darby canine kidney cells. Mol. Biol. Cell12, 2257–2274 (2001).
  • Nava P , LopezS, AriasCF, IslasS, Gonzalez-MariscalL. The rotavirus surface protein VP8 modulates the gate and fence function of tight junctions in epithelial cells. J. Cell Sci.117, 5509–5519 (2004).
  • Lindmark T , KimuraY, ArturssonP. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. J. Pharmacol. Exp. Ther.284, 362–369 (1998).
  • Cho SY , KimJS, LiH, ShimC, LinhardtRJ, KimYS. Enhancement of paracellular transport of heparin disaccharide across Caco-2 cell monolayers, Arch. Pharm. Res.25, 86–92 (2002).
  • Hecht G , KoutsourisA, PothoulakisC, LaMontJT, MadaraJL. Clostridium difficile toxin B disrupts the barrier function of T84 monolayers. Gastroenterology102, 416–423 (1992).
  • Simonovic I , RosenbergJ, KoutsourisA, HechtG. Enteropathogenic Escherichia coli dephosphorylates and dissociates occludin from intestinal epithelial tight junctions. Cell. Microbiol.2, 305–331 (2000).
  • Wong WR , HakozakiT, YoshiiT, Chen T-Y, Pang J-HS. Up-regulation of tight junction-related proteins and increase of human epidermal keratinocytes barrier function by Saccharomycosis ferment filtrate. J. Cosm. Dermatol. Sci. Appl.1, 15–24 (2011).
  • Uchida H , KondohM, HanadaT, TakahashiA, HamakuboT, YagiK. A claudin-4 modulator enhances the mucosal absorption of a biologically active peptide. Biochem. Pharmacol.79, 1437–1444 (2010).
  • Ebihara C , KondohM, HaradaMet al. Role of Tyr306 in the C-terminal fragment of Clostridium perfringens enterotoxin for modulation of tight junction. Biochem. Pharmacol. 73, 824–830 (2007).
  • Kondoh M , MasuyamaA, TakahashiAet al. A novel strategy for the enhancement of drug absorption using a claudin modulator. Mol. Pharmacol. 67, 749–756 (2005).
  • Sonoda N , FuruseM, SasakiHet al. Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands: evidence for direct involvement of claudins in tight junction barrier. J. Cell. Biol.147, 195–204 (1999).
  • Fetih G , HabibF, KatsumiHet al. Excellent absorption enhancing characteristics of NO donors for improving the intestinal absorption of poorly absorbable compound compared with conventional absorption enhancers. Drug Metab. Pharmacokinet. 21, 222–229 (2006).
  • Anderberg EK , NyströmC, ArturssonP. Epithelial transport of drugs in cell culture. VII: effects of pharmaceutical surfactant excipients and bile acidson transepithelial permeability in monolayers of human intestinal epithelial (Caco-2) cells. J. Pharm. Sci.81, 79–87 (1992).
  • Fetih G , HabibF, OkadaN, FujitaT, AttiaM, YamamotoA. Nitric oxide donors can enhance the intestinal transport and absorption of insulin and [Asu(1,7)]-eel calcitonin in rats. J. Control. Release106, 287–297 (2005).
  • Utoguchi N , WatanabeY, ShidaT, MatsumotoM. Nitric oxide donors enhance rectal absorption of macromolecules in rabbits. Pharm. Res.15, 870–876 (1998).
  • Watanabe Y , MatsumotoY, SekiM, TakaseM, MatsumotoM. Absorption enhancement of polypeptide drugs by cyclodextrins. I. Enhanced rectal absorption of insulin from hollow-type suppositories containing insulin and cyclodextrins in rabbits. Chem. Pharm. Bull. (Tokyo)40, 3042–3047 (1992).
  • Yang T , HussainA, PaulsonJ, AbbruscatoTJ, AhsanF. Cyclodextrins in nasal delivery of low-molecular-weight heparins: in vivo and in vitro studies. Pharm. Res.21, 1127–1136 (2004).
  • Lambert D , O‘NeillCA, PadfieldPJ. Methyl-beta-cyclodextrin increases permeability of Caco-2 cell monolayers by displacing specific claudins from cholesterol rich domains associated with tight junctions. Cell. Physiol. Biochem.20, 495–506 (2007).
  • Watanabe Y , MatsumotoY, KawamotoK, YazawaS, MatsumotoM. Enhancing effect of cyclodextrins on nasal absorption of insulin and its duration in rabbits. Chem. Pharm. Bull. (Tokyo)40, 3100–3104 (1992).
  • Song K -H, Fasano A, Eddington ND. Enhanced nasal absorption of hydrophilic markers after dosing with AT1002, a tight junction modulator. Eur. J. Pharm. Biopharm.69, 231–237 (2008).
  • Gopalakrishnan S , PandeyN, TamizAPet al. Mechanism of action of ZOT-derived peptide AT-1002, a tight junction regulator and absorption enhancer. Int. J. Pharm. 365, 121–130 (2009).
  • Chong S , FungHL. Transdermal drug delivery: pharmacokinetics, clinical efficacy, and tolerance development. In: Transdermal Drug Delivery: Developmental Issues and Research Initiatives. Hadgraft J, Guy RH (Eds). Marcel Dekker Inc., New York, NY, USA, 135–154 (1989).
  • Ryan DG , TimAP. 4 myths about transdermal drug delivery. Drug Deliv. Tech.3, 1–11 (2003).
  • Barry BW . Properties that influence percutaneous absorption. In: Dermatological Formulation and Percutaneous Absorption. Swarbrick J (Ed.). Marcel Dekker Inc., New York, NY, USA, 54–160 (1983).
  • Tien JH . Transdermal-controlled administration of oxycodone. J. Pharm. Sci.80, 741–743 (1991).
  • Shamim A , JerukoI, MasakiO. Stereo-selective hydrolysis and penetration of propranolol prodrugs, in vitro evaluation using hairless mouse skin. J. Pharm. Sci.84, 877–883 (1995).
  • Kurasawa M , KurodaS, KidaNet al. Regulation of tight junction permeability by sodium caprate in human keratinocytes and reconstructed epidermis. Biochem. Biophys. Res. Commun. 381, 171–175 (2009).
  • Prow TW , GriceJE, LinLLet al. Nanoparticles and microparticles for skin drug delivery. Adv. Drug Del. Rev. 63, 470–491 (2011).
  • Cardoso FL , BritesD, BritoMA. Looking at the blood–brain barrier: molecular anatomy and possible investigation approaches. Brain Res. Rev.64, 328–363 (2010).
  • Matter K , BaldaMS. Holey barrier: claudins and the regulation of brain endothelial permeability. J. Cell. Biol.161, 459–460 (2003).
  • Minagar A , AlexanderJS. Blood–brain barrier disruption in multiple sclerosis. Mult. Scler.9, 540–549 (2003).
  • Bennett J , BasivireddyJ, KollarAet al. Blood–brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE. J. Neuroimmunol. 229, 180–191 (2010).
  • Brooks TA , OcheltreeSM, SeelbachMJet al. Biphasic cytoarchitecture and functional changes in the BBB induced by chronic inflammatory pain. Brain Res. 1120, 172–182 (2006).
  • Maeda H , BharateGY, DaruwallaJ. Polymeric drugs for efficient tumortargeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm.71, 409–419 (2009).
  • Hynynen K . Ultrasound for drug and gene delivery to the brain. Adv. Drug Deliv. Rev.60, 1209–1217 (2008).
  • Demeule M , ReginaA, CheCet al. Identification and design of peptides as a new drug delivery system for the brain. J. Pharmacol. Exp. Ther. 324, 1064–1072 (2008).
  • Demeule M , CurrieJC, BertrandYet al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J. Neurochem. 106, 1534–1544 (2008).
  • Takahashi A , KondohM, SuzukiH, YagiK. Claudin as a target for drug development. Curr. Med. Chem.18, 1861–1865 (2011).
  • Kondoh M , YoshidaT, KakutaniH, YagiK. Targeting tight junction proteins – significance for drug development. Drug Discov. Today13, 180–186 (2008).
  • Zeisel MB , FofanaI, Fafi-KremerS, BaumertTF. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J. Hepatol.54, 566–576 (2011).
  • Mensa L , CrespoG, GastingerMJet al. Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics. Hepatology 53, 1436–1445 (2011).
  • Aveleira CA , LinCM, AbcouwerSF, AmbrósioAF, AntonettiDA. TNF-alpha signals through PKCζ/NF-KB to alter the tight junction complex and increase retinal endothelial cell permeability. Diabetes59, 2872–2882 (2010).
  • Leal EC , MartinsJ, VoabilPet al. Calcium dobesilate inhibits the alterations in tight junction proteins and leukocyte adhesion to retinal endothelial cells induced by diabetes. Diabetes 59, 2637–2645 (2010).
  • Cui HS , HayasakaS, ZhangXY, HayasakaY, ChiZL, ZhengLS. Effect of berberine on barrier function in a human retinal pigment epithelial cell line. Jpn J. Ophthalmol.51, 64–67 (2007).
  • Chen HQ , YangJ, ZhangMet al. Lactobacillus plantarum ameliorates colonic epithelial barrier dysfunction by modulating the apical junctional complex and PepT1 in IL- 10 knockout mice. Am. J. Physiol.299, G1287–G1297 (2010).
  • Sapra B , JainS, TiwaryAK. Effect of asparagus racemosus extract on transdermal delivery of carvedilol: a mechanistic study. AAPS Pharm. Sci. Tech.10, 199–210 (2009).
  • Kaufmann R , PiontekJ, GrüllFet al. Visualization and quantitative analysis of reconstituted tight junctions using localization microscopy. PLoS ONE 7(2), e31128 (2012).
  • Schlüter H , WepfR, IngridM, FrankeWW. Sealing the live part of the skin: the integrated meshwork of desmosomes, tight junctions and curvilinear ridge structures in the cells of the uppermost granular layer of the human epidermis. Eur. J. Cell. Biol.83, 655–665 (2004).
  • Inai T , SengokuA, HiroseE, IidaH, ShibataY. Freeze-fracture electron microscopic study of tight junction strands in HEK293 cells and MDCK II cells expressing claudin-1 mutants in the second extracellular loop. Histochem. Cell Biol.131, 681–690 (2009).
  • Kremers G -J, Gilbert SG, Cranfill PJ, Davidson MW, Piston DW. Fluorescent proteins at a glance. J. Cell Sci.124, 157–160 (2011).
  • Brandner JM , KiefS, GrundC, RendlM, HoudekP, KuhnC. Organization and formation of the tight junction system in human epidermis and cultured keratinocytes. Eur. J. Cell Biol.81, 253–263 (2002).
  • Sha X , YanG, WuY, LiJ, FangX. Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells. Eur. J. Pharm. Sci.24, 477–486 (2005).
  • Kong W , LiS, LiuCet al. Epithelial–mesenchymal transition occurs after epidermal development in mouse skin. Exp. Cell Res. 312, 3959–3968 (2006).
  • Schmidta E , KellybSM, van der Walle CF. Tight junction modulation and biochemical characterisation of the zonula occludens toxin C-and N-termini. FEBS Lett.581, 2974–2980 (2007).
  • Nagumo Y , HanJ, ArimotoM, IsodaH, TanakaT. Capsaicin induces cofilin dephosphorylation in human intestinal cells: the triggering role of cofilin in tight-junction signaling. Biochem. Biophys. Res. Comm.355, 520–525 (2007).
  • Sugibayashi K , OnukiY, TakayamaK. Displacement of tight junction proteins from detergent-resistant membrane domains by treatment with sodium caprate. Eur. J. Pharm. Sci.36, 246–253 (2009).
  • Takahashi A , KondohM, UchidaH, KakamuY, TakaoH, YagiK. Mutated C-terminal fragments of Clostridium perfringens enterotoxin have increased affinity to claudin-4 and reversibly modulate tight junctions in vitro. Biochem. Biophys. Res. Comm.410, 466–470 (2011).
  • Meng J , MostaghelEA, Vakar-LopezF, MontgomeryB, TrueL, NelsonPS. Testosterone regulates tight junction proteins and influences prostatic autoimmune responses. Horm. Cancer2, 145–156 (2011).
  • Toshihiro N , NobuhiroK, MasatoKet al. Irinotecan injures tight junction and causes bacterial translocation in rat. J. Surg. Res. 173, 341–347 (2012).
  • Yin Q , NanH, YanLet al. Alteration of tight junctions in pulmonary microvascular endothelial cells in bleomycin-treated rats. Exp. Toxicol. Pathol. 64, 81–91 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.